Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
15.38
-0.29 (-1.85%)
At close: Mar 27, 2026, 4:00 PM EDT
15.45
+0.07 (0.46%)
Pre-market: Mar 30, 2026, 4:25 AM EDT
Monte Rosa Therapeutics Revenue
In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth. Monte Rosa Therapeutics had revenue of $2.78M in the quarter ending December 31, 2025, a decrease of -95.41%.
Revenue (ttm)
$123.67M
Revenue Growth
+63.54%
P/S Ratio
9.95
Revenue / Employee
$824,480
Employees
150
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vir Biotechnology | 68.56M |
| Immatics | 56.67M |
| Wave Life Sciences | 42.73M |
| Taysha Gene Therapies | 9.77M |
| DBV Technologies | 5.64M |
| AtaiBeckley | 4.09M |
GLUE News
- 12 days ago - Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 13 days ago - Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
- 2 months ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire